biosimilars

As Sandoz prepares to spin off from Novartis, the company sets sights on new crosstown headquarters
As Sandoz prepares to spin off from Novartis, the company sets sights on new crosstown headquarters
Fierce Pharma
Novartis
biosimilars
spinoffs
headquarters
Flag link:
Amgen settles patent lawsuit over biosimilar of J&J's big-selling Stelara
Amgen settles patent lawsuit over biosimilar of J&J's big-selling Stelara
Yahoo/Reuters
JNJ
Amgen
patents
Stelara
biosimilars
legal
Flag link:
Novartis brings on 8 business vets for Sandoz's new board, including 4 women
Novartis brings on 8 business vets for Sandoz's new board, including 4 women
Fierce Pharma
Novartis
Sandoz
biosimilars
generics
women executives
Flag link:
Sandoz taps Evotec in long-term biosimilar development and manufacturing deal
Sandoz taps Evotec in long-term biosimilar development and manufacturing deal
Fierce Pharma
Novartis
Sandoz
Evotec
biosimilars
Flag link:
As Humira biosims take hold, longtime AbbVie CEO Richard Gonzalez talks succession plans
As Humira biosims take hold, longtime AbbVie CEO Richard Gonzalez talks succession plans
Fierce Pharma
AbbVie
Pharma CEOs
Richard Gonzalez
Humira
biosimilars
Flag link:
Teva's Partner Alvotech Receives Complete Response Letter For AVT02 BLA
Teva's Partner Alvotech Receives Complete Response Letter For AVT02 BLA
Business Insider
Teva Pharmaceutical
Alvotech
AVT02
FDA
Humira
biosimilars
Flag link:
FDA rejects Teva’s high-potency biosimilar of Humira again
FDA rejects Teva’s high-potency biosimilar of Humira again
Pharmaphorum
Teva Pharmaceutical
Alvotech
biosimilars
FDA
Humira
Flag link:
Amgen's denosumab shows promise in small, NIH-funded rare bone disease study
Amgen's denosumab shows promise in small, NIH-funded rare bone disease study
Endpoints
Amgen
Prolia
Xgeva
denosumab
clinical trials
NIH
biosimilars
monoclonal antibodies
Flag link:
Acquired patents aid J&J defense of top-selling drug from biosimilar challenge
Acquired patents aid J&J defense of top-selling drug from biosimilar challenge
BioPharma Dive
Amgen
JNJ
Stelara
psoriasis
patents
biosimilars
Flag link:
J&J finalizes $25M settlement, laying Remicade antitrust allegations to rest
J&J finalizes $25M settlement, laying Remicade antitrust allegations to rest
Endpoints
JNJ
legal
Remicade
antitrust
biosimilars
Flag link:
Sandoz, betting on biosimilar sales, to build new production plant
Sandoz, betting on biosimilar sales, to build new production plant
BioPharma Dive
Sandoz
Novartis
drug manufacturing
Slovenia
biosimilars
Flag link:
Citing J&J's 'failure to comply' with court rules, judge nixes early bid to block Amgen's Stelara biosim
Citing J&J's 'failure to comply' with court rules, judge nixes early bid to block Amgen's Stelara biosim
Fierce Pharma
JNJ
patents
Janssen
Amgen
biosimilars
Stelara
Flag link:
Could This Humira Biosimilar Be a Winner for Amgen?
Could This Humira Biosimilar Be a Winner for Amgen?
Motley Fool
Amgen
biosimilars
Amjevita
Humira
Flag link:
Doctors largely comfortable with biosimilar drugs, but question economics: report
Doctors largely comfortable with biosimilar drugs, but question economics: report
BioPharma Dive
Cardinal Health
physicians
biosimilars
Flag link:
Big pharma’s looming threat: a patent cliff of ‘tectonic magnitude’
Big pharma’s looming threat: a patent cliff of ‘tectonic magnitude’
BioPharma Dive
Big Pharma
patents
patent cliff
biosimilars
AbbVie
Humira
Merck
Keytruda
Bristol Myers Squibb
Opdivo
Flag link:
Fresenius Kabi introduces pegfilgrastim biosimilar for cancer patients in US
Fresenius Kabi introduces pegfilgrastim biosimilar for cancer patients in US
Pharmaceutical Business Review
Fresenius Kabi
Stimufend
pegfilgrastim
biosimilars
Neulasta
Amgen
cancer
Flag link:
Years after the first US biosim launches, doctors still have their concerns: survey
Years after the first US biosim launches, doctors still have their concerns: survey
Fierce Pharma
biosimilars
PBMs
physicians
AbbVie
Humira
Amgen
Amjevita
Flag link:
FDA rejects Biocon and Viatris' Avastin biosimilar after inspection question marks
FDA rejects Biocon and Viatris' Avastin biosimilar after inspection question marks
Endpoints
FDA
Biocon
Viatris
Avastin
biosimilars
drug manufacturing
Flag link:
AbbVie talks next steps as first Humira competitor makes it to market
AbbVie talks next steps as first Humira competitor makes it to market
Endpoints
AbbVie
Humira
biosimilars
Rick Gonzalez
Flag link:
Sandoz files biosimilar of Amgen osteoporosis drug in US
Sandoz files biosimilar of Amgen osteoporosis drug in US
Pharmaphorum
Sandoz
Novartis
biosimilars
osteoporosis
Prolia
Xgeva
FDA
Flag link:

Pages